Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.45 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24009992 | 0.97 | ALDH1A1 (0.50) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL24010843 | 0.89 | MAPT (0.53) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL25824173 | 0.88 | KMT2A (0.57) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL23999691 | 0.87 | IP6K1 (0.46) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL25826714 | 0.85 | NCF1 (0.44) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL24003938 | 0.84 | IP6K1 (0.43) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL25826713 | 0.82 | NCF1 (0.41) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL24004017 | 0.80 | TSHR (0.60) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL23999730 | 0.80 | KMT2A (0.43) | ALDH1A1KDM4EMEN1POLBMAPT | |
| SCHEMBL26329960 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4EMEN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ALDH1A1 4544/4885KDM4E 3961/4885MEN1 1926/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ALDH1A1 4541/4885KDM4E 4095/4885MEN1 1948/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | ALDH1A1 3871/4885KDM4E 4219/4885MEN1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.